201286-65-9

Basic information

• Product Name: 4-BROMO-3,5-DIMETHYLPYRIDINE
• Synonyms: 4-BROMO-3,5-DIMETHYLPYRIDINE;4-Bromo-3,5-dimethylpyridine hydrochloride;4-Bromo-3,5-lutidine hydrochloride;4-Bromo-3,5-dimethylpyridine HCl
• CAS NO: 201286-65-9
• Molecular Formula: C₇H₈BrN
• Molecular Weight: 186.05
• Product Categories: Pyridine series;Building Blocks;Pyridine
• Mol File: 201286-65-9.mol

Chemical Properties

• Boiling Point: 235.5±35.0 °C(Predicted)
• Appearance: /
• Density: 1.415±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 3.81±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-3,5-DIMETHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-3,5-DIMETHYLPYRIDINE(201286-65-9)
• EPA Substance Registry System: 4-BROMO-3,5-DIMETHYLPYRIDINE(201286-65-9)

Safety Data

• Hazardous Substances Data: 201286-65-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-3,5-dimethylpyridine is used as a key intermediate in the synthesis of Sulfonyl Indoles and related Bicyclic compounds. These compounds act as modulators of Liver X Receptor (LXR), which play a crucial role in regulating lipid metabolism, inflammation, and glucose homeostasis. By modulating LXR activity, these compounds can be employed for the treatment and prevention of LXR-mediated diseases, such as atherosclerosis, non-alcoholic steatohepatitis, and diabetes.

Upstream product

• 591-22-0 3,5-Lutidine 
• 70564-92-0 4-bromo-3,5-dimethyl-pyridine 1-oxide 
• 14248-66-9 3,5-dimethyl-4-nitropyridine-1-oxide 
• 7789-60-8 phosphorus tribromide 

Downstream Products

• 201286-64-8 3,5-dimethylpyridine-4-carbaldehyde 
• 1032358-02-3 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2yl)-pyridine 
• 1032358-13-6 4-(3,5-di-tert-butyl-4-methoxyphenyl)-3,5-dimethylpyridine 

Relevant articles and documents

Halogen Bonding Molecular Capsules

Molecular capsules based solely on the interaction of halogen bonding (XB) are presented along with their host-guest binding properties in solution. The first example of a well-defined four-point XB supramolecular system is realized by decorating resorcin[4]arene cavitands with polarized halogen atoms for dimerization with tetra(4-pyridyl) resorcin[4]arene cavitands. NMR binding data for the F, Cl, Br, and I cavitands as the XB donor show association constants (Ka) of up to 5370 M-1 (ΔG283 K=-4.85 kcal mol-1, for I), even in XB-competitive solvent, such as deuterated benzene/acetone/methanol (70:30:1) at 283 K, where comparable monodentate model systems show no association. The XB capsular geometry is evidenced by two-dimensional HOESY NMR, and the thermodynamic profile shows that capsule formation is enthalpically driven. Either 1,4-dioxane or 1,4-dithiane are encapsulated within each of the two separate cavities within the XB capsule, with of up to Ka=9.0 108 M-2 (ΔG283 K=-11.6 kcal mol-1).

Syntheses of sterically hindered zwitterionic pyridinium phenolates as model compounds in nonlinear optics

Pyridinium phenolates possess a dissymmetric delocalised π-electron system providing a huge quadratic nonlinearity. They are a promising class of molecules for applications in photoelectronics and photonics. Semiempirical calculations indicate that the interplanar angle between the two aromatic rings leads to enhancement in the NLO properties of these compounds. The confirmation of this feature may be provided by the study of a new series of sterically hindered pyridinium phenolates 2a-e bearing two tert-butyl substituents at the ortho position(s) of the phenolate functionality. Such bulky groups would enhance the solubility of zwitterions in organic solvents and would limit the formation of aggregates. Their efficient preparations by using Suzuki cross-coupling reactions involving 3,5-dialkylated 4-bromopyridine N-oxides are described herein. Wiley-VCH Verlag GmbH & Co. KGaA, 2008.

TETRACYCLIC INHIBITORS OF JANUS KINASES

The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.

Substituted azabicyclic compounds

This invention is directed to certain physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; and N-oxides thereof, and their prodrugs, and pharmaceutically acceptable salts and solvates of the compounds of formula (I) and N-oxides thereof, and their prodrugs. Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmaceutical compositions comprising compounds of formula (I), their pharmaceutical use and methods for their preparation.